- Viral Genetics, Inc. (OTC:VRAL), a biotechnology company that discovers and develops immune-based therapies, today unveiled to the general public initial findings of its ongoing Lyme Disease study.
Sphere: Related ContentIf you’re new here, you may want to subscribe to my RSS feed. Thanks for visiting!
